Leap Therapeutics (LPTX)
(Delayed Data from NSDQ)
$2.56 USD
+0.09 (3.64%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $2.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Income Statements
Fiscal Year end for Leap Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 2 | 2 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 2 | 2 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 87 | 57 | 43 | 30 | 33 |
Income After Depreciation & Amortization | -87 | -57 | -41 | -29 | -33 |
Non-Operating Income | 6 | 2 | 1 | 1 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -81 | -54 | -41 | -28 | -33 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -81 | -55 | -41 | -28 | -33 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -81 | -55 | -41 | -28 | -33 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -87 | -57 | -41 | -28 | -33 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -87 | -57 | -41 | -29 | -33 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 20.45 | 11.32 | 8.58 | 5.93 | 2.26 |
Diluted EPS Before Non-Recurring Items | -3.98 | -4.80 | -4.70 | -6.30 | -14.70 |
Diluted Net EPS (GAAP) | -3.98 | -4.80 | -4.70 | -6.30 | -14.70 |
Fiscal Year end for Leap Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 21.26 | 14.83 | 14.83 | 14.83 | 14.66 |
Income After SG&A, R&D, and Dept/Amort Expenses | -21.26 | -14.83 | -14.83 | -14.83 | -14.66 |
Non-Operating Income | 1.12 | 1.01 | 2.36 | 1.14 | 1.27 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -20.13 | -13.82 | -12.47 | -13.70 | -13.39 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -20.13 | -13.82 | -12.47 | -13.70 | -13.39 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -20.13 | -13.82 | -12.47 | -13.70 | -13.39 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 39.12 | 27.01 | 26.99 | 26.99 | 14.71 |
Diluted EPS Before Non-Recurring Items | -0.52 | -0.51 | -0.46 | -0.51 | -0.91 |
Diluted Net EPS (GAAP) | -0.52 | -0.51 | 0.64 | -0.51 | -0.91 |